Raaijmakers J A M
Universiteit Utrecht, Inst.Farmaceutische Wetenschappen, afd. Farmacoepidemiologie en Farmacotherapie, Postbus 80.082, 3508 TB Utrecht.
Ned Tijdschr Geneeskd. 2006 Aug 12;150(32):1768.
The conflicts of interest dominate discussions on collaborative research between academic institutions and the pharmaceutical industry. Although one should not be blind to such possibilities and remain critical, the advantages outweigh the risks by far. The remaining diseases for which adequate pharmacotherapy is lacking are complex and require an expensive research infrastructure. Therefore, progress will benefit from collaboration and should not be hindered by short-sightedness.
利益冲突主导着关于学术机构与制药行业之间合作研究的讨论。尽管人们不应忽视这种可能性并应保持批判性，但优势远大于风险。目前仍缺乏充分药物治疗的疾病很复杂，需要昂贵的研究基础设施。因此，合作将推动进展，不应因短视而受阻。
